Han Y, Du B, Zhu X, Wang Y, Zheng H, Liu W
Front Endocrinol (Lausanne). 2024; 15:1336402.
PMID: 38742197
PMC: 11089115.
DOI: 10.3389/fendo.2024.1336402.
Ning Y, Zhou X, Wang G, Zhang L, Wang J
Curr Diabetes Rev. 2024; 21(2):e070524229720.
PMID: 38712372
DOI: 10.2174/0115733998297749240418071555.
Song C, Zhu Z, Liu L, Liu S, Li Y, Xiao Y
Front Pharmacol. 2023; 14:1180751.
PMID: 37475716
PMC: 10354524.
DOI: 10.3389/fphar.2023.1180751.
Sun G, Jiao M, Cui Y, Liang X, Liang X, Zhang S
Ann Transl Med. 2023; 10(24):1329.
PMID: 36660701
PMC: 9843345.
DOI: 10.21037/atm-22-5035.
Nourizadeh N, Vazifeh Mostaan L, Saburi E, Hashemy S
Mol Biol Rep. 2022; 49(11):10885-10893.
PMID: 35941413
DOI: 10.1007/s11033-022-07623-7.
Implications of Sphingolipid Metabolites in Kidney Diseases.
Mallela S, Merscher S, Fornoni A
Int J Mol Sci. 2022; 23(8).
PMID: 35457062
PMC: 9025012.
DOI: 10.3390/ijms23084244.
The apoM/S1P Complex-A Mediator in Kidney Biology and Disease?.
Bisgaard L, Christoffersen C
Front Med (Lausanne). 2021; 8:754490.
PMID: 34722589
PMC: 8553247.
DOI: 10.3389/fmed.2021.754490.
New insights into renal lipid dysmetabolism in diabetic kidney disease.
Mitrofanova A, Burke G, Merscher S, Fornoni A
World J Diabetes. 2021; 12(5):524-540.
PMID: 33995842
PMC: 8107981.
DOI: 10.4239/wjd.v12.i5.524.
Synthesis and characterization of [I]TZ6544, a promising radioligand for investigating sphingosine-1-phosphate receptor 2.
Luo Z, Liang Q, Liu H, Sumit J, Jiang H, Klein R
Nucl Med Biol. 2020; 88-89:52-61.
PMID: 32791475
PMC: 8972069.
DOI: 10.1016/j.nucmedbio.2020.07.007.
as a Potential Treatment Agent for Type 2 Diabetes Mellitus and the Underlying Mechanisms: A Review.
Ran Q, Wang J, Wang L, Zeng H, Yang X, Huang Q
Front Pharmacol. 2019; 10:805.
PMID: 31396083
PMC: 6661542.
DOI: 10.3389/fphar.2019.00805.
Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics.
Feng X, Sureda A, Jafari S, Memariani Z, Tewari D, Annunziata G
Theranostics. 2019; 9(7):1923-1951.
PMID: 31037148
PMC: 6485276.
DOI: 10.7150/thno.30787.
Interaction between sphingosine kinase/sphingosine 1 phosphate and transforming growth factor-β/Smads pathways in experimental intestinal fibrosis. An in vivo immunohistochemical study.
Sferra R, Pompili S, Ventura L, Dubuquoy C, Speca S, Gaudio E
Eur J Histochem. 2018; 62(3).
PMID: 30064196
PMC: 6077868.
DOI: 10.4081/ejh.2018.2956.
Sphingosine-1-phosphate pathway in renal fibrosis.
Zhang X, Ritter J, Li N
Am J Physiol Renal Physiol. 2018; 315(4):F752-F756.
PMID: 29631354
PMC: 6230725.
DOI: 10.1152/ajprenal.00596.2017.
Modulation of sphingosine 1-phosphate (S1P) attenuates spatial learning and memory impairments in the valproic acid rat model of autism.
Wu H, Zhang Q, Gao J, Sun C, Wang J, Xia W
Psychopharmacology (Berl). 2017; 235(3):873-886.
PMID: 29218394
DOI: 10.1007/s00213-017-4805-4.
Sphingosine kinase 1 mediates AGEs-induced fibronectin upregulation in diabetic nephropathy.
Chen C, Gong W, Li C, Xiong F, Wang S, Huang J
Oncotarget. 2017; 8(45):78660-78676.
PMID: 29108256
PMC: 5667989.
DOI: 10.18632/oncotarget.20205.
and its constituent berberine as antidotes and protective agents against natural or chemical toxicities.
Mohammadzadeh N, Mehri S, Hosseinzadeh H
Iran J Basic Med Sci. 2017; 20(5):538-551.
PMID: 28656089
PMC: 5478782.
DOI: 10.22038/IJBMS.2017.8678.
Mammalian sphingosine kinase (SphK) isoenzymes and isoform expression: challenges for SphK as an oncotarget.
Hatoum D, Haddadi N, Lin Y, Nassif N, McGowan E
Oncotarget. 2017; 8(22):36898-36929.
PMID: 28415564
PMC: 5482707.
DOI: 10.18632/oncotarget.16370.
Phloretin exerts hypoglycemic effect in streptozotocin-induced diabetic rats and improves insulin resistance in vitro.
Shen X, Zhou N, Mi L, Hu Z, Wang L, Liu X
Drug Des Devel Ther. 2017; 11:313-324.
PMID: 28223777
PMC: 5304989.
DOI: 10.2147/DDDT.S127010.
The role of sphingolipid signalling in diabetes‑associated pathologies (Review).
Ng M, Wadham C, Sukocheva O
Int J Mol Med. 2017; 39(2):243-252.
PMID: 28075451
PMC: 5358714.
DOI: 10.3892/ijmm.2017.2855.
TGR5 suppresses high glucose-induced upregulation of fibronectin and transforming growth factor-β1 in rat glomerular mesangial cells by inhibiting RhoA/ROCK signaling.
Xiong F, Li X, Yang Z, Wang Y, Gong W, Huang J
Endocrine. 2016; 54(3):657-670.
PMID: 27470217
DOI: 10.1007/s12020-016-1032-4.